What is Monte Rosa Therapeutics, Inc.'s earnings per share (EPS)?

Monte Rosa Therapeutics, Inc. (GLUE) reported diluted earnings per share of $-0.46 for fiscal year 2025. This represents a 53.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Monte Rosa Therapeutics, Inc. Financials

GLUE

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Monte Rosa Therapeutics, Inc. (GLUE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GLUE FY2025 2026-05-07

FY2025 shows a revenue-funded narrowing of operating losses, but cash still behaves like a financed resource rather than a self-renewing one.

Better reported economics did not improve cash generation: revenue rose to $123.7M and net loss nearly halved to -$38.6M in FY2025, yet operating cash flow fell back to -$22.8M from $42.0M in FY2024. That gap implies FY2024’s positive cash flow was not the start of durable self-funding, while FY2025’s operating margin of -43.8% shows revenue scale absorbed more of a still-rising R&D base rather than improvement driven by austerity.

Short-term liquidity improved for a balance-sheet reason, not a cash-build reason: the current ratio jumped to 6.1x from 2.4x even though cash fell to $129.9M from $224.3M, because current liabilities dropped to $64.2M from $156.9M. Near-term obligations became lighter even as the cash cushion shrank.

The company still runs an investment-heavy operating model: FY2025 R&D reached $141.5M, above revenue of $123.7M, and share count rose to 65.5M from 61.5M while financing cash added $30.4M. That mix says the income statement is improving, but the business has not yet fully shifted from external funding to internally generated cash.

Financial Health Signals

Financial Health Score 56/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Monte Rosa Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Monte Rosa Therapeutics, Inc. has an operating margin of -43.8%, meaning the company retains $-44 of operating profit per $100 of revenue. This below-average margin results in a low score of 24/100, suggesting thin profitability after operating expenses. This is up from -107.3% the prior year.

Growth

Monte Rosa Therapeutics, Inc.'s revenue surged 63.5% year-over-year to $123.7M, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

Monte Rosa Therapeutics, Inc. has a moderate D/E ratio of 0.93. This balance of debt and equity financing earns a leverage score of 48/100.

Liquidity

With a current ratio of 6.12, Monte Rosa Therapeutics, Inc. holds $6.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.

Cash Flow

While Monte Rosa Therapeutics, Inc. generated -$22.8M in operating cash flow, capex of $4.7M consumed most of it, leaving -$27.5M in free cash flow. This results in a low score of 47/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Monte Rosa Therapeutics, Inc.'s ROE of -16.6% shows moderate profitability relative to equity, earning a score of 30/100. This is up from -32.6% the prior year.

Altman Z-Score Safe

5.03

Monte Rosa Therapeutics, Inc. scores 5.03, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($215.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Monte Rosa Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.59x

For every $1 of reported earnings, Monte Rosa Therapeutics, Inc. generates $0.59 in operating cash flow (-$22.8M OCF vs -$38.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$123.7M

YoY+63.5%

Monte Rosa Therapeutics, Inc. generated $123.7M in revenue in fiscal year 2025. This represents an increase of 63.5% from the prior year.

EBITDA

-$43.4M

YoY+38.8%

Monte Rosa Therapeutics, Inc.'s EBITDA was -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.8% from the prior year.

Net Income

-$38.6M

YoY+46.9%

Monte Rosa Therapeutics, Inc. reported -$38.6M in net income in fiscal year 2025. This represents an increase of 46.9% from the prior year.

EPS (Diluted)

$-0.46

YoY+53.1%

Monte Rosa Therapeutics, Inc. earned $-0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.5M

YoY-172.3%

Monte Rosa Therapeutics, Inc. generated -$27.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 172.3% from the prior year.

Cash & Debt

$129.9M

YoY-42.1%

5Y CAGR+25.5%

Monte Rosa Therapeutics, Inc. held $129.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

66M

YoY+6.6%

Monte Rosa Therapeutics, Inc. had 66M shares outstanding in fiscal year 2025. This represents an increase of 6.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-43.8%

YoY+63.4pp

Monte Rosa Therapeutics, Inc.'s operating margin was -43.8% in fiscal year 2025, reflecting core business profitability. This is up 63.4 percentage points from the prior year.

Net Margin

-31.2%

YoY+64.9pp

Monte Rosa Therapeutics, Inc.'s net profit margin was -31.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 64.9 percentage points from the prior year.

Return on Equity

-16.6%

YoY+16.1pp

Monte Rosa Therapeutics, Inc.'s ROE was -16.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 16.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$141.5M

YoY+16.4%

5Y CAGR+42.6%

Monte Rosa Therapeutics, Inc. invested $141.5M in research and development in fiscal year 2025. This represents an increase of 16.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4.7M

YoY+17.9%

5Y CAGR+6.8%

Monte Rosa Therapeutics, Inc. invested $4.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 17.9% from the prior year.

GLUE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$123.7M+63.5%	$75.6M	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$141.5M+16.4%	$121.6M+9.2%	$111.3M+30.8%	$85.1M+48.8%	$57.2M+138.1%	$24.0M
SG&A Expenses	$36.4M+3.4%	$35.2M+9.8%	$32.0M+17.3%	$27.3M+73.7%	$15.7M+292.7%	$4.0M
Operating Income	-$54.2M+33.2%	-$81.1M+43.4%	-$143.3M-27.5%	-$112.4M-54.2%	-$72.9M-160.2%	-$28.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$1.1M-142.7%	$2.6M+660.4%	$338K	$0	N/A	N/A
Net Income	-$38.6M+46.9%	-$72.7M+46.3%	-$135.4M-24.7%	-$108.5M-46.7%	-$74.0M-106.1%	-$35.9M
EPS (Diluted)	$-0.46+53.1%	$-0.98+62.7%	$-2.63-14.3%	$-2.30+22.3%	$-2.96	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$4.2M+51.4%	$2.8M-78.2%	$12.8M-45.0%	$23.2M-72.7%	$84.9M+40.0%	$60.6M+558.1%	$9.2M+96.3%	$4.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$44.1M+5.0%	$42.0M+14.5%	$36.7M+19.7%	$30.7M-4.8%	$32.2M-17.2%	$38.9M+40.7%	$27.6M-1.6%	$28.1M
SG&A Expenses	$10.2M-3.3%	$10.5M+16.0%	$9.1M+12.0%	$8.1M-7.0%	$8.7M-0.8%	$8.8M+8.0%	$8.1M-12.4%	$9.3M
Operating Income	-$50.0M-0.6%	-$49.7M-50.8%	-$33.0M-112.0%	-$15.6M-135.3%	$44.0M+238.6%	$13.0M+149.0%	-$26.5M+18.7%	-$32.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$52K-11.9%	$59K+101.9%	-$3.2M-365.0%	$1.2M+45.9%	$822K-62.0%	$2.2M+2947.9%	$71K-71.8%	$252K
Net Income	-$44.5M+3.5%	-$46.1M-70.3%	-$27.1M-120.3%	-$12.3M-126.2%	$46.9M+248.9%	$13.4M+156.3%	-$23.9M+21.3%	-$30.3M
EPS (Diluted)	$-0.45	N/A	$-0.33-120.0%	$-0.15-126.3%	$0.57	N/A	$-0.29+32.6%	$-0.43

GLUE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$448.7M+2.3%	$438.7M+44.4%	$303.8M-11.3%	$342.4M-6.5%	$366.3M+641.9%	$49.4M
Current Assets	$393.2M+4.2%	$377.4M+59.8%	$236.2M-14.4%	$275.9M-20.9%	$348.7M+699.9%	$43.6M
Cash & Equivalents	$129.9M-42.1%	$224.3M+75.1%	$128.1M+133.3%	$54.9M-84.1%	$346.1M+729.9%	$41.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$215.6M-0.1%	$215.8M+73.3%	$124.5M+75.4%	$71.0M+277.3%	$18.8M-80.8%	$98.1M
Current Liabilities	$64.2M-59.1%	$156.9M+236.9%	$46.6M+82.2%	$25.6M+53.7%	$16.6M-43.2%	$29.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$233.1M+4.5%	$222.9M+24.4%	$179.3M-34.0%	$271.4M-21.9%	$347.5M+813.2%	-$48.7M
Retained Earnings	-$477.2M-8.8%	-$438.6M-19.9%	-$365.9M-58.7%	-$230.5M-88.9%	-$122.0M-153.8%	-$48.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$736.4M+64.1%	$448.7M-2.4%	$459.8M+27.9%	$359.6M-8.5%	$393.2M-10.4%	$438.7M+39.2%	$315.1M-8.4%	$344.1M
Current Assets	$677.5M+72.3%	$393.2M-2.1%	$401.8M+34.2%	$299.5M-9.9%	$332.3M-12.0%	$377.4M+50.3%	$251.2M-9.6%	$277.9M
Cash & Equivalents	$159.9M+23.1%	$129.9M-37.7%	$208.3M+200.1%	$69.4M-11.6%	$78.5M-65.0%	$224.3M+78.6%	$125.6M+15.4%	$108.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$9.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$214.5M-0.5%	$215.6M+0.7%	$214.0M+133.9%	$91.5M-22.5%	$118.0M-45.3%	$215.8M+96.9%	$109.6M-8.2%	$119.4M
Current Liabilities	$71.0M+10.6%	$64.2M+4.5%	$61.4M+46.8%	$41.9M-29.3%	$59.2M-62.3%	$156.9M+276.9%	$41.6M-1.7%	$42.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$521.9M+123.9%	$233.1M-5.2%	$245.8M-8.3%	$268.1M-2.6%	$275.2M+23.4%	$222.9M+8.5%	$205.5M-8.6%	$224.7M
Retained Earnings	-$521.7M-9.3%	-$477.2M-10.7%	-$431.1M-6.7%	-$404.0M-3.1%	-$391.7M+10.7%	-$438.6M+3.0%	-$452.0M-5.6%	-$428.2M

GLUE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$22.8M-154.3%	$42.0M+195.9%	-$43.8M+52.6%	-$92.5M-55.8%	-$59.4M-157.5%	-$23.1M
Capital Expenditures	$4.7M+17.9%	$4.0M-79.1%	$19.0M+47.5%	$12.9M+32.7%	$9.7M+187.2%	$3.4M
Free Cash Flow	-$27.5M-172.3%	$38.0M+160.5%	-$62.8M+40.4%	-$105.4M-52.5%	-$69.1M-161.3%	-$26.4M
Investing Cash Flow	-$101.8M-129.1%	-$44.5M-150.1%	$88.8M+140.5%	-$219.2M-2171.0%	-$9.7M-184.8%	-$3.4M
Financing Cash Flow	$30.4M-69.3%	$98.9M+259.7%	$27.5M+34.3%	$20.5M-94.6%	$377.6M+528.6%	$60.1M
Dividends Paid	$0	$0	$0	$0	$0	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$37.4M+13.1%	-$43.0M-142.8%	$100.4M+389.3%	-$34.7M+23.7%	-$45.5M-135.3%	$128.9M+714.1%	-$21.0M+24.4%	-$27.8M
Capital Expenditures	$1.9M+143.5%	$767K+17.8%	$651K-61.6%	$1.7M+6.8%	$1.6M+767.2%	$183K-54.1%	$399K-80.3%	$2.0M
Free Cash Flow	-$39.2M+10.4%	-$43.8M-143.9%	$99.8M+374.0%	-$36.4M+22.7%	-$47.1M-136.6%	$128.7M+701.8%	-$21.4M+28.2%	-$29.8M
Investing Cash Flow	-$261.0M-301.1%	-$65.1M-270.6%	$38.1M+50.6%	$25.3M+125.3%	-$100.2M-224.4%	-$30.9M-181.8%	$37.7M+161.7%	-$61.2M
Financing Cash Flow	$328.3M+1008.3%	$29.6M+8412.6%	$348K-4.7%	$365K+2507.1%	$14K-97.7%	$608K+3953.3%	$15K-100.0%	$98.0M
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GLUE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-43.8%+63.4pp	-107.3%	N/A	N/A	N/A	N/A
Net Margin	-31.2%+64.9pp	-96.1%	N/A	N/A	N/A	N/A
Return on Equity	-16.6%+16.1pp	-32.6%+42.9pp	-75.5%-35.5pp	-40.0%-18.7pp	-21.3%	N/A
Return on Assets	-8.6%+8.0pp	-16.6%+28.0pp	-44.6%-12.9pp	-31.7%-11.5pp	-20.2%+52.5pp	-72.7%
Current Ratio	6.12+3.7	2.40-2.7	5.07-5.7	10.79-10.2	20.96+19.5	1.49
Debt-to-Equity	0.93-0.0	0.97+0.3	0.69+0.4	0.26+0.2	0.05+2.1	-2.01
FCF Margin	-22.2%-72.5pp	50.3%	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1188.5%+599.2pp	-1787.7%-1529.4pp	-258.3%-191.2pp	-67.1%-118.9pp	51.8%+30.4pp	21.4%+309.3pp	-287.8%+407.4pp	-695.3%
Net Margin	-1057.1%+600.9pp	-1658.0%-1445.9pp	-212.1%-159.1pp	-53.0%-108.2pp	55.2%+33.0pp	22.2%+281.1pp	-258.9%+386.7pp	-645.6%
Return on Equity	-8.5%+11.3pp	-19.8%-8.8pp	-11.0%-6.4pp	-4.6%-21.6pp	17.0%+11.0pp	6.0%+17.6pp	-11.6%+1.9pp	-13.5%
Return on Assets	-6.0%+4.2pp	-10.3%-4.4pp	-5.9%-2.5pp	-3.4%-15.3pp	11.9%+8.9pp	3.1%+10.6pp	-7.6%+1.2pp	-8.8%
Current Ratio	9.54+3.4	6.12-0.4	6.54-0.6	7.16+1.5	5.61+3.2	2.40-3.6	6.03-0.5	6.56
Debt-to-Equity	0.41-0.5	0.93+0.1	0.87+0.5	0.34-0.1	0.43-0.5	0.97+0.4	0.530.0	0.53
FCF Margin	-932.0%+642.3pp	-1574.3%-2355.8pp	781.5%+938.5pp	-157.0%-101.6pp	-55.4%-267.7pp	212.3%+444.4pp	-232.1%+402.4pp	-634.5%

Similar Companies

enGene Therapeutics Inc ENGN

$124.6M

Design Therapeutics, Inc. DSGN

$954.3M

Contineum Therapeutics CTNM

$585.1M

4D Molecular Therapeutics Inc. FDMT

$680.6M

Alpha Tau Medical Ltd DRTS

$1.2B

Frequently Asked Questions

What is Monte Rosa Therapeutics, Inc.'s annual revenue?

Monte Rosa Therapeutics, Inc. (GLUE) reported $123.7M in total revenue for fiscal year 2025. This represents a 63.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Monte Rosa Therapeutics, Inc.'s revenue growing?

Monte Rosa Therapeutics, Inc. (GLUE) revenue grew by 63.5% year-over-year, from $75.6M to $123.7M in fiscal year 2025.

Is Monte Rosa Therapeutics, Inc. profitable?

No, Monte Rosa Therapeutics, Inc. (GLUE) reported a net income of -$38.6M in fiscal year 2025, with a net profit margin of -31.2%.

What is Monte Rosa Therapeutics, Inc.'s EBITDA?

Monte Rosa Therapeutics, Inc. (GLUE) had EBITDA of -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Monte Rosa Therapeutics, Inc.'s operating margin?

Monte Rosa Therapeutics, Inc. (GLUE) had an operating margin of -43.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Monte Rosa Therapeutics, Inc.'s net profit margin?

Monte Rosa Therapeutics, Inc. (GLUE) had a net profit margin of -31.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Monte Rosa Therapeutics, Inc.'s return on equity (ROE)?

Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity of -16.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Monte Rosa Therapeutics, Inc.'s free cash flow?

Monte Rosa Therapeutics, Inc. (GLUE) generated -$27.5M in free cash flow during fiscal year 2025. This represents a -172.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Monte Rosa Therapeutics, Inc.'s operating cash flow?

Monte Rosa Therapeutics, Inc. (GLUE) generated -$22.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Monte Rosa Therapeutics, Inc.'s total assets?

Monte Rosa Therapeutics, Inc. (GLUE) had $448.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Monte Rosa Therapeutics, Inc.'s capital expenditures?

Monte Rosa Therapeutics, Inc. (GLUE) invested $4.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Monte Rosa Therapeutics, Inc. spend on research and development?

Monte Rosa Therapeutics, Inc. (GLUE) invested $141.5M in research and development during fiscal year 2025.

How many shares does Monte Rosa Therapeutics, Inc. have outstanding?

Monte Rosa Therapeutics, Inc. (GLUE) had 66M shares outstanding as of fiscal year 2025.

What is Monte Rosa Therapeutics, Inc.'s current ratio?

Monte Rosa Therapeutics, Inc. (GLUE) had a current ratio of 6.12 as of fiscal year 2025, which is generally considered healthy.

What is Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio?

Monte Rosa Therapeutics, Inc. (GLUE) had a debt-to-equity ratio of 0.93 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Monte Rosa Therapeutics, Inc.'s return on assets (ROA)?

Monte Rosa Therapeutics, Inc. (GLUE) had a return on assets of -8.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Monte Rosa Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Monte Rosa Therapeutics, Inc. (GLUE) had $129.9M in cash against an annual operating cash burn of $22.8M. This gives an estimated cash runway of approximately 68 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Monte Rosa Therapeutics, Inc.'s Altman Z-Score?

Monte Rosa Therapeutics, Inc. (GLUE) has an Altman Z-Score of 5.03, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Monte Rosa Therapeutics, Inc.'s Piotroski F-Score?

Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Monte Rosa Therapeutics, Inc.'s earnings high quality?

Monte Rosa Therapeutics, Inc. (GLUE) has an earnings quality ratio of 0.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Monte Rosa Therapeutics, Inc.?

Monte Rosa Therapeutics, Inc. (GLUE) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.